Sector News

Stada's buyout bombs, failing to get enough shareholder support

June 27, 2017
Life sciences

German generics maker Stada is back on the market. Just weeks after announcing a €5.32 billion ($5.63 billion) buyout by private equity investors, the deal has failed, unable to get enough support from shareholders.

Stada in May agreed to be acquired by London-based private equity firm Cinven and Boston investment firm Bain Capital for essentially €66 a share, a 48.9% premium. But Monday it announced they had secured commitments from only 65.52% of shareholders, instead of the required 67.5%. The investors had already lowered the threshold for approval from 75%.

Stada called it a show of support for its current strategy, but sources told Reuters it was more likely scuttled because retail investors that held Stada shares in index funds had ignored the call for their approval. About 27% of Stada’s shares are held by retail investors.

“We respect the close vote of our shareholders and understand it as a mandate to press ahead with our successful growth strategy,” Stada Chairman Matthias Wiedenfels, said in a statement. “However, we also regard this decision as a mark of confidence in STADA’s abilities, which our employees have impressively demonstrated, in particular over the past months.”

German takeover rules complicate another run at the company by Bain and Cinven. They would have to submit an entirely new offer and get Stada shareholders to agree to it within the year, Reuters said.

There is a chance that Boston private equity firm Advent International might make another offer for the company. It had proposed a $3.7 billion buyout of Stada in February, but the drugmaker chose instead to hold out for higher offers.

In an effort to attract those, Stada in March laid out a cost-cutting plan and boosted its sales and earnings forecasts significantly. It projected a 2019 adjusted EBITDA target range of between €570 million to €590 million ($612.8 million to $634.3 million) up from its earlier projection of €510 million ($548.3 million).

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.